The safety of convalescent plasma (Podcast Episode 31)

Guest: Michael J. Joyner, M.D. (@DrMJoyner)

Host: Amit K. Ghosh, M.D., M.B.A. (@AmitGhosh006)

Convalescent plasma as a passive immunity strategy is not new. What nuances apply for its application to treating COVID-19? Is it safe? Is it efficacious? Michael J. Joyner, M.D., principal investigator for Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19, discusses what's known about this treatment option, information that's currently being gathered and how you can get involved.

AABB coronavirus resources: http://www.aabb.org/advocacy/regulatorygovernment/Pages/AABB-Coronavirus-Resources.aspx 

AskMayoExpert COVID-19 Navigator resources: https://askmayoexpert.mayoclinic.org/navigator/COVID-19

This education is supported in part by an independent medical education grant from Pfizer Inc. and is in accordance with ACCME guidelines.

Click here to claim credit and view faculty disclosures. Select Register to begin the credit claim process.

Connect with Mayo Clinic School of Continuous Professional Development online at https://ce.mayo.edu or on Twitter @MayoMedEd.


Published

August 6, 2020

Created by

Mayo Clinic